To examine whether addition of agonistic anti-CD134 mAb21,22 improves the survival of mice treated with anti-CD20 mAb we employed the syngeneic B-cell lymphoma model, BCL1 (Fig. 1A). The gene discussed is TNFRSF4; the disease is B-cell non-Hodgkin lymphoma.